Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 05 May, 2020

JP Morgan Sec LLC

AbbVie Inc. 38.5(b)

RNS Number : 9817L
J.P. Morgan Securities LLC
05 May 2020
 

Ap27

 

 

FORM   38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.  KEY   INFORMATION

 

Nameofexemptprincipaltrader

J.P Morgan Securities LLC

Companydealtin

AbbVie Inc.

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 1)

Common stock

Date of dealing

4 May 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   2)

 

 

Long

Short

 

Number

 

(%)

Number

 

(%)

 10,711,168  0.73

 3,981,542  0.27

(2) Derivatives (other than options)

 5,748,779  0.39

 8,129,059  0.55

(3)Optionsandagreementstopurchase/sell

 767,000  0.05

 773,100  0.05

Total

 17,226,947  1.17

 12,883,701  0.87

             

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   2)

 

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

 

 

(2) Derivatives (other than options)

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap28

 

 

3.  DEALINGS  (Note   3)

 

(a)  Purchases and sales

 

Purchase/sale

Numberofrelevantsecurities

Priceperunit (Note 4)

Sale (Borrow Return)

 

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

576,500

 

395

8

8

167

500

314

59

30

177

287

100

63

64

9,985

50

125

300

71

96

100

113

85

65

100

143

277

31

200

98

31

219

90

300

100

100

100

17

124

200

323

275

203

23

2

8

430

66

5

90

191

112

3

22

37

61

8

 

2

2

1

1

790

4

100

2

2

6

2

4

2

2

1

2

8

83

2

42

2

2

2

4

2

1

4

4

2

5

83

1

2

4

59

500

73

59

5

2

1

9

3

1

71

42

1

67

1

1

2

2

1

19

900

64

76

4

1

8

70

80

3

3

2

2

2

1

4

9

2

7

9

1

14

17

6

1

7

3

64

100

8

NA

 

81.2700 USD

81.4400 USD

81.4425 USD

81.4887 USD

81.6336 USD

81.6845 USD

81.7200 USD

81.7412 USD

81.7957 USD

81.8109 USD

81.8368 USD

81.8524 USD

81.8595 USD

81.8600 USD

81.8976 USD

81.9048 USD

81.9267 USD

81.9300 USD

81.9325 USD

81.9327 USD

81.9350 USD

81.9400 USD

81.9451 USD

81.9500 USD

81.9529 USD

81.9600 USD

81.9649 USD

81.9700 USD

81.9715 USD

81.9784 USD

81.9800 USD

81.9864 USD

81.9900 USD

82.0000 USD

82.0100 USD

82.0200 USD

82.0400 USD

82.0505 USD

82.0650 USD

82.0828 USD

82.0835 USD

82.0842 USD

82.0857 USD

82.0949 USD

82.1129 USD

82.1228 USD

82.1575 USD

82.1639 USD

82.1641 USD

82.1830 USD

82.1867 USD

82.1957 USD

82.2328 USD

82.2396 USD

82.3400 USD

82.8400 USD

 

81.2000 USD

81.2100 USD

81.2300 USD

81.2600 USD

81.2700 USD

81.2900 USD

81.3070 USD

81.3100 USD

81.3200 USD

81.3633 USD

81.3700 USD

81.3800 USD

81.4000 USD

81.4200 USD

81.4300 USD

81.4400 USD

81.4425 USD

81.4574 USD

81.4800 USD

81.4985 USD

81.5100 USD

81.5200 USD

81.5300 USD

81.5400 USD

81.5500 USD

81.5600 USD

81.5700 USD

81.5850 USD

81.5900 USD

81.5920 USD

81.6036 USD

81.6100 USD

81.6200 USD

81.6300 USD

81.6329 USD

81.6336 USD

81.6338 USD

81.6480 USD

81.6500 USD

81.6600 USD

81.6700 USD

81.6756 USD

81.6800 USD

81.6900 USD

81.6946 USD

81.6950 USD

81.7000 USD

81.7187 USD

81.7300 USD

81.7500 USD

81.7550 USD

81.7800 USD

81.8200 USD

81.8463 USD

81.8544 USD

81.8595 USD

81.8600 USD

81.8700 USD

81.8800 USD

81.8963 USD

81.8964 USD

81.9100 USD

81.9200 USD

81.9267 USD

81.9300 USD

81.9350 USD

81.9400 USD

81.9500 USD

81.9900 USD

81.9944 USD

81.9950 USD

81.9971 USD

82.0167 USD

82.0300 USD

82.0707 USD

82.0835 USD

82.1400 USD

82.1500 USD

82.1586 USD

82.1900 USD

82.2300 USD

82.2500 USD

82.8400 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 5)

Numberofrelevantsecurities

(Note 6)

Priceperunit

(USD)

(Note 4)

Equity Swaps

Long

 

 

Short

395

64

 

8

500

40

81.2700

81.8595

 

81.4425

81.6336

81.8600

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing,   selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 4)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 4)

 

 

 

 

 

(d)  Other   dealings   (including   transactions   in   respect   of   new   securities)   (Note   3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Ap29

 

4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached?  (Note   8)    YES

 

 

Dateofdisclosure

5 May 2020

Contactname

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 

 

Ap31

 

 

SUPPLEMENTAL   FORM   38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS   OF OPEN POSITIONS

 

(This   form   should   be   attached   to   Form   38.5(b))   OPEN POSITIONS  (Note   1)

 

Productname,

e.g. call option

Written orpurchased

Numberofrelevant securitiestowhichtheoptionorderivativerelates

Exercise price (Note 2)

Type, e.g.American,Europeanetc.

Expiry date

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

10,000

6,100

41,200

8,400

11,200

7,200

21,100

2,500

7,900

5,600

2,500

8,500

10,000

100,000

200

50,600

600

2,000

200

15,000

15,000

200

20,000

7,900

9,500

8,500

6,100

18,200

8,400

11,200

7,200

21,100

2,500

4,500

5,600

2,500

100

300

300

1,000

20,000

100

15,000

15,000

100

20,000

102,500

31,300

32,300

16,400

65,000

900

7,000

4,400

45,000

29,100

9,700

8,300

12,300

13,300

1,000

140,000

5,100

9,000

2,800

20,000

15,000

15,000

20,000

102,500

31,300

32,300

11,400

8,900

1,900

4,400

29,100

20,000

1,700

100,000

600

100

3,000

1,100

15,000

15,000

20,000

1,600

1,200

700

1,800

105.00

110.00

85.00

92.50

95.00

100.00

80.00

87.50

90.00

97.50

115.00

105.00

110.00

70.00

85.00

92.50

95.00

100.00

90.00

91.57

95.93

97.50

82.37

95.00

100.00

105.00

110.00

85.00

92.50

95.00

100.00

80.00

87.50

90.00

97.50

115.00

85.00

92.50

95.00

100.00

82.50

90.00

91.57

95.93

97.50

82.37

60.00

65.00

70.00

75.00

77.50

85.00

72.50

67.50

80.00

55.00

60.00

65.00

70.00

75.00

77.50

82.50

62.50

72.50

67.50

80.00

78.49

82.85

78.35

60.00

65.00

70.00

75.00

77.50

72.50

67.50

55.00

60.00

65.00

70.00

75.00

77.50

72.50

67.50

78.49

82.85

78.35

75.00

77.50

72.50

80.00

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

18SEP20

18SEP20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

15JAN21

18SEP20

18SEP20

18SEP20

18SEP20

 

 

 

 

Notes

 

1.  Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.  For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEBGGDUXSGDGGU

a d v e r t i s e m e n t